Business
iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of two Non-Executive Directors to its Board.
About this update from Genmab A/s
[{"type":"list","items":[{"val":[{"type":"text","content":"Neil Gallagher M.D., Ph.D., former AbbVie Chief Medical Officer and President of R&D at Syndax, brings considerable experience in oncology drug development","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"Anthony Mancini, currently Global Chief Commercial Officer at Revolution Medicines, led several successful oncology product launches at Genmab and BMS","length":150,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":309,"olType":false},{"type":"text","content":"GENEVA, AMSTERDAM, and CAMBRIDGE, Mass., July 24, 2025 /PRNewswire/ -- iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of two Non-Executive Directors to its Board.","length":248,"tagName":"p"},{"type":"image","alt":"iOnctura Logo","displaySize":"","headline":null,"caption":"iOnctura Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":86,"url":"https://media.zenfs.com/en/prnewswire.com/11972ceeeca0affbf0b2d5da644ab0d1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8xREJtfjvexA07Hd8X8nig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/11972ceeeca0affbf0b2d5da644ab0d1","width":400,"height":86}},"href":"https://mma.prnewswire.com/media/2736715/iOnctura_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Joining the Board are Dr. Neil Gallagher and Anthony Mancini, both seasoned industry leaders with deep expertise in oncology drug development and commercialization.","length":164,"tagName":"p"},{"type":"text","content":"Catherine Pickering, CEO and co-founder of iOnctura, commented, "We are thrilled to welcome Neil and Anthony to our Board at this pivotal time in iOnctura's growth. Their expertise and experience in oncology drug development and global commercialization will be instrumental as we progress our innovative pipeline through development and towards the market."","length":377,"tagName":"p"},{"type":"text","content":"Neil Gallagher M.D., Ph.D. brings substantial drug development experience in oncology. Most recently he was President of R&D at Syndax Pharmaceuticals, a company focused on developing first-in-class therapies in areas of significant unmet need. Prior to joining Syndax, h...